Glaukos (GKOS) news
Recent news
Glaukos Corporation - IdoSe TR demonstrates favorable safety profile through 3 months
AInvest Wire · 3d agoGlaukos Corporation - Phase 4 study meets primary efficacy endpoint with statistically significant IOP reduction
AInvest Wire · 3d agoGlaukos: Positive topline results from phase 4 prospective randomized controlled clinical trial evaluating IDose8 TR in
AInvest Wire · 3d agoGlaukos to develop Ro-104 tri-specific retinal biologic
Glaukos Corporation has announced a strategic initiative to develop Ro-104, a tri-specific retinal biologic, as part of its ongoing efforts to expand its portfolio in ophthalmic therapeutics. The biologic is designed to target multiple pathways involved in retinal disease progression, potentially…
AInvest Wire · 4d agoGlaukos announces exclusive license pact with Revopsis
Glaukos Corporation has entered into an exclusive license agreement with Revopsis, granting the latter rights to develop and commercialize a novel intraocular lens (IOL) technology for the treatment of glaucoma. Under the terms of the agreement, Revopsis will have exclusive rights to utilize…
AInvest Wire · 4d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.